Association between *ZFHX3* and *PRR X1* polymorphisms and atrial fibrillation susceptibility

Liting Wu

Shanghai shidong yiyuan: Yangpu District Shidong Hospital of Shanghai

Ming Chu

Shanghai shidong yiyuan: Yangpu District Shidong Hospital of Shanghai

Wenfang Zhuang (✉ czwf1991@163.com)

Shanghai shidong yiyuan: Yangpu District Shidong Hospital of Shanghai

Research Article

Keywords: zinc finger homeobox 3, paired related homeobox 1, atrial fibrillation, polymorphism, risk

Posted Date: June 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-370715/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background Atrial fibrillation (AF) is a common, sustained cardiac arrhythmia. Recent studies have reported an association between ZFHX3/PRRX1 polymorphisms and AF. In this study, a meta-analysis was conducted to confirm these associations.

Methods The PubMed, Embase, and Wanfang databases were searched, covering all publications before July 20, 2020.

Results Overall, seven articles including 3,674 cases and 8,990 healthy controls for ZFHX3 rs2106261 and 1045 cases and 1407 controls for PRRX1 rs3903239 were included. The odds ratio (OR) [95% confidence interval (CI)] was used to assess the associations. Publication bias was calculated using Egger's and Begg's tests. We found that the ZFHX3 rs2106261 polymorphism increased AF risk in Asians (for example, allelic contrast: OR [95% CI]: 1.39 [1.31–1.47], $P < 0.001$). Similarly, strong associations were detected through stratified analysis using source of control and genotype methods (for example, allelic contrast: OR [95% CI]: 1.51 [1.38–1.64], $P < 0.001$ for HB; OR [95% CI]: 1.31 [1.21–1.41], $P < 0.001$ for PB; OR [95% CI]: 1.55 [1.33–1.80], $P < 0.001$ for TaqMan; OR [95% CI]: 1.31 [1.21–1.41], $P < 0.001$ for high-resolution melt). In contrast, an inverse relationship was observed between the PRRX1 rs3903239 polymorphism and AF risk (C-allele vs. T-allele: OR [95% CI]: 0.83 [0.77–0.99], $P = 0.036$; CT vs. TT: OR [95% CI]: 0.79 [0.67–0.94], $P = 0.006$). No obvious evidence of publication bias was observed.

Conclusion In summary, our study suggests that the ZFHX3 rs2106261 and PRRX1 rs3903239 polymorphisms are associated with AF risk, and larger case-controls must be carried out to confirm the above conclusions.

Background

Atrial fibrillation (AF) is a common form of arrhythmia, with an incidence of approximately 1% among adults worldwide[1, 2]. Previous studies have demonstrated that AF significantly increases the social and economic burden in both developed and developing countries[3]. Additionally, AF is the main cause of heart failure and stroke[4, 5]. A variety of structural heart diseases and systemic diseases are related to AF, including congestive heart failure, cardiomyopathy, pulmonary heart disease, essential hypertension, and hyperthyroidism[6, 7], while age, obesity, smoking, excessive drinking, and drug use also contribute to the development of AF[6, 8]. Thus far, the exact pathogenesis of AF remains unclear. However, many studies have suggested that genetic factors play an important role in AF occurrence and development[9]. In fact, common genetic variants (a multitude of single-nucleotide polymorphisms [SNPs]) associated with AF have been detected in genome-wide association studies (GWASs)[10–12], such as endothelial nitric oxide synthase 786T/C, CYP11B2 rs1799998, *KCNE1* G38S, and caveolin-1 rs3807989[9, 13–15].

Two independent GWASs identified significant associations between rs2106261 and rs7193343 polymorphisms in the zinc finger homeobox 3 (*ZFHX3*) gene and AF susceptibility in various populations of European ancestry[16, 17]. *ZFHX3* is located on chromosome 16q22. Benjamin et al.[16] indicated that the rs2106261 SNP in *ZFHX3* was associated with AF (OR = 1.19; $P = 2.76 \times 10^{-7}$). At the same time, Gudbjartsson et al.[17] assessed another SNP (rs7193343) in *ZFHX3*, which was confirmed to be related to AF in Icelandic individuals (OR = 1.21, $P = 1.4 \times 10^{-10}$).

Paired homeobox 1 (*PRRX1*) encodes a homeodomain transcription factor that is highly expressed in the developing heart[18]. Fetal lung vascular development was impaired in a *PRRX1* knockout mouse model[19]. The expression pattern of *PRRX1* in mouse atria was evaluated; both genes were overexpressed in the left atrium when compared to the right atrium[20]. These results suggest that PRRX1 may play a vital role in heart diseases, including AF. In a subsequent meta-GWAS, the *PRRX1* rs3903239 variant was associated with AF risk ($P = 8.4 \times 10^{-14}$)[21].

Taking into consideration the more precise assessment of the *ZFHX3* rs2106261 and *PRRX1* rs3903239 variants in AF risk, we must first perform a meta-analysis of all eligible case-control studies to confirm the associations[18, 22–27].

Materials And Methods

Identification and eligibility of relevant studies

The PubMed, Embase, and Wanfang databases were selected. The last search was conducted on July 20, 2020, with the search terms including the keywords “ZFHX3” or “zinc finger homeobox 3,” “PRRX1” or “paired related homeobox 1,” “polymorphism” or “variant,” and “atrial fibrillation.” After the above search, a total of 96 publications were identified, of which 7 met the inclusion criteria.

Criteria for inclusion and exclusion

The studies included in the analysis met all of the following conditions: (a) the study assessed the correlation between AF and the *ZFHX3* rs2106261 polymorphism and/or *PRRX1* rs3903239 polymorphism; (b) unpaired case-control studies; (c) sufficient genotypes in cases and controls. In addition, the following exclusion criteria were applied: (a) no control group; (b) no genotype frequency was available; and (c) previous publications were repeated.

Data extraction

Two of the authors extracted all data independently and complied with the selection criteria. The following items were collected: author's name, ethnicity, year of publication, total of each genotype case/control number, country, source of control, genotyping methods, and Hardy-Weinberg equilibrium (HWE) of controls.

Quality score assessment (NOS)

NOS was used to assess the quality of each study and evaluate all aspects of the methodology, including case selection, comparability between groups, and exposure determination. The NOS has a total score of 0–9 stars. Research with a score greater than 7 is considered a high-quality study[28].

Statistical analysis

Based on the genotype frequencies of the cases and controls, the probability odds ratio (OR) with 95% confidence interval (CI) was used to measure the strength of association between the polymorphisms and AF. First, we conducted a subgroup analysis stratified by race. The source of the control subgroup analysis was carried out in two categories: population-based (PB) and hospital-based (HB).

The statistical significance of the OR was determined using the Z-test. The fixed and random effect models were used to calculate the combined OR. The *Q*-test ($P \geq 0.10$) indicated heterogeneity between the included studies. If significant heterogeneity was detected, the random effects model (DerSimonian-Laird method) was used, but otherwise, the fixed effects model (Mantel-Haenszel method) was selected[29, 30]. For *ZFHX3* rs2106261, we investigated the relationship between genetic variants and AF risk in allelic contrast (A-allele vs. G-allele), homozygote comparison (AA vs. GG), dominant genetic model (AA+AG vs. GG), heterozygote comparison (AG vs. GG), and recessive genetic models (AA vs. AG+GG). For *PRRX1* rs3903239, C-allele vs. T-allele, CT vs. TT, CC vs. TT, CC+CT vs. TT, and CC vs. CT+TT models were applied. Funnel plot asymmetry was assessed using Begg's test, and publication bias was assessed using Egger's test[31]. The departure of frequencies from expectation under HWE was assessed using the χ^2 test in the controls through the Pearson chi-square test ($P < 0.05$ was considered significant)[32]. All statistical tests for this meta-analysis were performed using Stata software (version 11.0; StataCorp LP, College Station, TX, USA).

ZFHX3 and *PRRX1* interaction networks

To fully understand the role and potential functional partners of *ZFHX3* and *PRRX1* in AF, the String online server (<http://string-db.org/>) was used to create a gene–gene interaction network of *ZFHX3* and *PRRX1*(Figure 10)[33].

Results

Eligible studies

In total, 96 articles were collected from the PubMed, Embase, and Wanfang databases. Of these, 89 articles were excluded (25 unrelated articles, 4 systematic/meta-analysis studies, 1 with only a case group, 23 supplements, 30 duplications, and 6 with no original numbers for case/control groups) (Figure 1). Finally, seven articles were identified in the current analysis, including 3,674 cases and 8,990 healthy controls related to the *ZFHX3* rs2106261 polymorphism and 1045 cases and 1407 controls for the *PRRX1* rs3903239 polymorphism. The

characteristics of each study are presented in Table 1. In addition, the minor allele frequency (MAF) reported from the five main worldwide populations in the 1000 Genomes Browser were checked (<https://www.ncbi.nlm.nih.gov/snp/>): African, European, East Asian, American, and South Asian populations (Figure 2); the MAF was similar to the average level in our current case and control groups.

ZFHX3 rs2106261 and AF risk

In the overall analysis, increased associations were observed in five genetic models in Asians: allelic contrast (OR [95% CI] = 1.39 [1.31–1.47], $P_{\text{heterogeneity}} = 0.117$, $P < 0.001$, Figure 3A), heterozygote comparison (OR [95% CI] = 1.37 [1.18–1.59], $P_{\text{heterogeneity}} = 0.007$, $P < 0.001$, Figure 3B), AA vs. CC (OR [95% CI] = 1.96 [1.73–2.21], $P_{\text{heterogeneity}} = 0.317$, $P < 0.001$, Figure 3C), the dominant model (OR [95% CI] = 1.49 [1.30–1.70], $P_{\text{heterogeneity}} = 0.011$, $P < 0.001$, Figure 3D), and AA vs. AC + CC (OR [95% CI] = 1.70 [1.52–1.90], $P_{\text{heterogeneity}} = 0.643$, $P < 0.001$, Figure 3E) (Table 2).

In the subgroup analysis by source of control, the ZFHX3 rs2106261 A allele or AA genotype acted as a risk factor in both HB and PB subgroups: HB (such as: A-allele vs. C-allele: OR [95% CI] = 1.51 [1.38–1.64], $P_{\text{heterogeneity}} = 0.302$, $P < 0.001$; AC vs. CC: OR [95% CI] = 1.57 [1.38–1.79], $P_{\text{heterogeneity}} = 0.156$, $P < 0.001$), and PB (such as: A-allele vs. C-allele: OR [95% CI] = 1.31 [1.21–1.41], $P_{\text{heterogeneity}} = 0.321$, $P < 0.001$; AC vs. CC: OR [95% CI] = 1.17 [1.04–1.30], $P_{\text{heterogeneity}} = 0.584$, $P = 0.007$) (Figure 3A,B, Table 2).

To detect whether an association exists between genotype methods and the ZFHX3 rs2106261 polymorphism, we performed the next step. Several positive results were found in TaqMan [in the allelic contrast (OR = 1.55, 95% CI = 1.33–1.80, $P = 0.740$ for heterogeneity, $P < 0.001$ for significance), the heterozygote comparison (OR = 1.82, 95% CI = 1.46–2.27, $P = 0.668$ for heterogeneity, $P < 0.001$), AA vs. CC (OR = 2.06, 95% CI = 1.48–2.86, $P_{\text{heterogeneity}} = 0.884$, $P < 0.001$ for significance), the dominant model (OR [95% CI] = 1.87 [1.52–2.30], $P_{\text{heterogeneity}} = 0.674$, $P < 0.001$), and AA vs. AC + CC (OR [95% CI] = 1.51 [1.11–2.06], $P_{\text{heterogeneity}} = 1.000$, $P < 0.001$), high-resolution melt [in the allelic contrast (OR = 1.31, 95% CI = 1.21–1.41, $P_{\text{heterogeneity}} = 0.647$, $P < 0.001$), the heterozygote comparison (OR = 1.17, 95% CI = 1.04–1.30, $P = 0.584$ for heterogeneity, $P = 0.007$ for significance), AA vs. CC (OR = 1.81, 95% CI = 1.54–2.12, $P_{\text{heterogeneity}} = 0.417$, $P < 0.001$), the dominant model (OR = 1.29, 95% CI = 1.16–1.43, $P = 0.655$ for heterogeneity, $P < 0.001$), and AA vs. AC + CC (OR = 1.68, 95% CI = 1.45–1.94, $P_{\text{heterogeneity}} = 0.384$, $P < 0.001$ for significance) and others (data not shown)] (Figure 4, Table 2).

PRRX1 rs3903239 and AF risk

Decreased associations were found in the heterozygote comparison (OR [95% CI] = 0.83 [0.77–0.99], $P_{\text{heterogeneity}} = 0.522$, $P = 0.036$, Figure 5A, Table 2) and dominant model (OR [95% CI] = 0.79 [0.67–0.94], $P = 0.137$ for heterogeneity, $P = 0.006$, Figure 5B, Table 2).

Sensitivity analysis and publication bias

A Begg's funnel chart and Egger's test were performed to assess publication bias. The results did not show any evidence of publication bias (for example, A-allele vs. G-allele, $t = 1.46$, $P = 0.205$ [Egger's test]; $z = 1.2$, $P = 0.23$ [Begg's test] for ZFHX3 rs2106261, Figure 6; C-allele vs. T-allele, $t = 0.11$, $P = 0.933$ [Egger's test]; $z = 0.0$, $P = 1.00$ [Begg's test] for PRRX1 rs3903239, Figure 7, Table 3). Sensitivity analysis was performed to assess the impact of each individual study on the combined OR by removing individual studies sequentially. The results suggested that no separate study significantly affected the overall OR for ZFHX3 rs2106261 (Figure 8).

ZFHX3 and PRRX1 interaction networks

A network of potential gene-gene interactions for ZFHX3 and PRRX1 genes was analyzed using the String online webpage (<http://string-db.org/>) [33] (Figure 9). Each gene showed ten significantly related genes.

Discussion

AF is considered to be the most common supraventricular arrhythmia, affecting up to 1% of the natural population[34, 35]. With increasing age, the prevalence rate increases year by year, and the incidence of elderly cases (≥ 80 years) can reach 8%[36]. Many types of heart and medical diseases that increase the risk of AF include arterial hypertension, cardiomyopathies, obstructive sleep apnea, and valve dysfunction[37, 38]. In addition, based on a recent meta-analysis of GWAS for AF[11], more than 100 AF risk genetic mutations and polymorphisms have been reported, indicating that gene polymorphisms are involved in the mechanisms of AF. An increasing number of studies have shown that genetic variation may promote the pathophysiology of AF by altering protein expression and function related to various cellular activities[39].

To date, several meta-analyses of gene polymorphisms and AF susceptibility have been published and have identified associations, including chromosome 4q25 variants, *CYP11B2* -344T>C, and *mink* S38G[40-43]. A growing number of studies have identified polymorphisms in both *ZFHX3* and *PRRX1*, although they have not been reported through meta-analysis studies that could clarify their associations with AF susceptibility.

The current analysis is the first to evaluate the associations between *ZFHX3* rs2106261 and *PRRX1* rs3903239 polymorphisms and AF risk, involving 4719 cases and 10397 controls. We found a relationship between *ZFHX3* rs2106261 and AF risk; in contrast, the *PRRX1* rs3903239 polymorphism functioned as a protective factor in AF development. In other words, individuals carrying the A-allele of the *ZFHX3* rs2106261 polymorphism may have a high risk of AF. Individuals with the CC or CT genotype of *PRRX1* might have a decreased risk for AF. These findings can help reduce the incidence of AF through early detection and possible prevention measures. Different genes or polymorphisms in the same genes may play multiple functions in the progression of AF, and this may explain the above conclusions.

In addition, the online analysis system String was applied to predict the potential functional partners of the genes, which may help to expand the range of vision of related genes. Ten genes were identified. The three highest scores of associations were for cyclin-dependent kinase inhibitor 1A (*CDKN1A*) (score = 0.921), runt-related transcription factor 3 (*RUNX3*) (score = 0.918) and transforming growth factor-beta 1 (*TGF β 1*) (score = 0.900). Several studies have focused on *CDKN1A* and *TGF β 1*, but not *RUNX3*, in the development of AF. Further studies should focus on the above three potentially related genes and their common polymorphisms in AF. On the contrary, the scores of related genes for *PRRX1* are generally low; however, this should be verified and indicated in future research.

Although positive results were found, limitations of the current study should also be discussed. First, the literature included is relatively new, and the number of published studies is not sufficiently large. Second, the gene-gene/gene-environment interactions (other covariates including family history, age, sex, disease stage, and lifestyle) and even variant polymorphisms in the same genes may regulate AF risk and must be included in further studies. Third, there are several types of AF, such as persistent, permanent, pathologic, idiopathic, and paroxysmal. If enough data exist for the different types of AF in the future, we could classify the analysis into subgroups prior to analyzing the association of the *ZFHX3* rs2106261 and *PRRX1* rs3903239 polymorphisms with AF, which could offer more precise findings for faster translation to the clinic.

Conclusions

Our analysis illustrated that the *ZFHX3* rs2106261 and *PRRX1* rs3903239 polymorphisms are associated with conspicuous AF risk in Asians. Therefore, well-designed and larger studies, including information about gene-gene/gene-environment interactions, are recommended to confirm the above conclusions.

Abbreviations

AF, atrial fibrillation; *ZFHX3*, zinc finger homeobox 3; *PRRX1*, paired related homeobox 1, confidence intervals; HWE, Hardy-Weinberg equilibrium; OR, odds ratio.

Declarations

Acknowledgements

Not applicable

Author Contribution

L.W. conceived the study. M.C. searched the databases and extracted the data. W.Z. analyzed the data. L.W. wrote the draft of the paper. W.Z. reviewed the manuscript.

Funding

None

Availability of data and materials

All data generated or analyzed in this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors proclaim that they have no competing interests.

References

- 1 Luo, X., Li, B., Zhang, D., Zhu, J., Qi, L. and Tang, Y. (2019) Efficacy and safety of the convergent atrial fibrillation procedure: a meta-analysis of observational studies. *Interactive cardiovascular and thoracic surgery*. **28**, 169-176
- 2 Rahman, F., Kwan, G. F. and Benjamin, E. J. (2014) Global epidemiology of atrial fibrillation. *Nature reviews. Cardiology*. **11**, 639-654
- 3 Wang, X. J., Ding, P., Wang, F. Z. and Liu, Q. (2019) Correlations of SCN5A gene polymorphisms with onset of atrial fibrillation. *European review for medical and pharmacological sciences*. **23**, 7089-7097
- 4 Hu, D. and Sun, Y. (2008) Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. *Journal of the American College of Cardiology*. **52**, 865-868
- 5 Roberts, J. D. and Gollob, M. H. (2010) Impact of genetic discoveries on the classification of lone atrial fibrillation. *Journal of the American College of Cardiology*. **55**, 705-712
- 6 Armaganijan, L., Lopes, R. D., Healey, J. S., Piccini, J. P., Nair, G. M. and Morillo, C. A. (2011) Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. *Clinics (Sao Paulo, Brazil)*. **66**, 1923-1928
- 7 Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J. Y., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L. and Wann, L. S. (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Journal of the American College of Cardiology*. **57**, e101-198
- 8 Saritas, A., Kandis, H., Baltaci, D. and Erdem, I. (2011) Paroxysmal atrial fibrillation and intermittent left bundle branch block: an unusual electrocardiographic presentation of mad honey poisoning. *Clinics (Sao Paulo, Brazil)*. **66**, 1651-1653

- 9 Wang, X., Li, Y. and Li, Q. (2019) A comprehensive meta-analysis on relationship between CYP11B2 rs1799998 polymorphism and atrial fibrillation. *Journal of electrocardiology*. **52**, 101-105
- 10 Nielsen, J. B., Thorolfssdottir, R. B., Fritsche, L. G., Zhou, W., Skov, M. W., Graham, S. E., Herron, T. J., McCarthy, S., Schmidt, E. M., Sveinbjornsson, G., Surakka, I., Mathis, M. R., Yamazaki, M., Crawford, R. D., Gabrielsen, M. E., Skogholt, A. H., Holmen, O. L., Lin, M., Wolford, B. N., Dey, R., Dalen, H., Sulem, P., Chung, J. H., Backman, J. D., Arnar, D. O., Thorsteinsdottir, U., Baras, A., O'Dushlaine, C., Holst, A. G., Wen, X., Hornsby, W., Dewey, F. E., Boehnke, M., Kheterpal, S., Mukherjee, B., Lee, S., Kang, H. M., Holm, H., Kitzman, J., Shavit, J. A., Jalife, J., Brummett, C. M., Teslovich, T. M., Carey, D. J., Gudbjartsson, D. F., Stefansson, K., Abecasis, G. R., Hveem, K. and Willer, C. J. (2018) Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. *Nature genetics*. **50**, 1234-1239
- 11 Roselli, C., Chaffin, M. D., Weng, L. C., Aeschbacher, S., Ahlberg, G., Albert, C. M., Almgren, P., Alonso, A., Anderson, C. D., Aragam, K. G., Arking, D. E., Barnard, J., Bartz, T. M., Benjamin, E. J., Bihlmeyer, N. A., Bis, J. C., Bloom, H. L., Boerwinkle, E., Bottinger, E. B., Brody, J. A., Calkins, H., Campbell, A., Cappola, T. P., Carlquist, J., Chasman, D. I., Chen, L. Y., Chen, Y. I., Choi, E. K., Choi, S. H., Christophersen, I. E., Chung, M. K., Cole, J. W., Conen, D., Cook, J., Crijns, H. J., Cutler, M. J., Damrauer, S. M., Daniels, B. R., Darbar, D., Delgado, G., Denny, J. C., Dichgans, M., Dörr, M., Dudink, E. A., Dudley, S. C., Esa, N., Esko, T., Eskola, M., Fatkin, D., Felix, S. B., Ford, I., Franco, O. H., Geelhoed, B., Grewal, R. P., Gudnason, V., Guo, X., Gupta, N., Gustafsson, S., Gutmann, R., Hamsten, A., Harris, T. B., Hayward, C., Heckbert, S. R., Hernesniemi, J., Hocking, L. J., Hofman, A., Horimoto, A., Huang, J., Huang, P. L., Huffman, J., Ingelsson, E., Ipek, E. G., Ito, K., Jimenez-Conde, J., Johnson, R., Jukema, J. W., Kääb, S., Kähönen, M., Kamatani, Y., Kane, J. P., Kastrati, A., Kathiresan, S., Katschnig-Winter, P., Kavousi, M., Kessler, T., Kietselaer, B. L., Kirchhof, P., Kleber, M. E., Knight, S., Krieger, J. E., Kubo, M., Launer, L. J., Laurikka, J., Lehtimäki, T., Leineweber, K., Lemaître, R. N., Li, M., Lim, H. E., Lin, H. J., Lin, H., Lind, L., Lindgren, C. M., Lokki, M. L., London, B., Loos, R. J. F., Low, S. K., Lu, Y., Lyytikäinen, L. P., Macfarlane, P. W., Magnusson, P. K., Mahajan, A., Malik, R., Mansur, A. J., Marcus, G. M., Margolin, L., Margulies, K. B., März, W., McManus, D. D., Melander, O., Mohanty, S., Montgomery, J. A., Morley, M. P., Morris, A. P., Müller-Nurasyid, M., Natale, A., Nazarian, S., Neumann, B., Newton-Cheh, C., Niemeijer, M. N., Nikus, K., Nilsson, P., Noordam, R., Oellers, H., Olesen, M. S., Orho-Melander, M., Padmanabhan, S., Pak, H. N., Paré, G., Pedersen, N. L., Pera, J., Pereira, A., Porteous, D., Psaty, B. M., Pulit, S. L., Pullinger, C. R., Rader, D. J., Refsgaard, L., Ribasés, M., Ridker, P. M., Rienstra, M., Risch, L., Roden, D. M., Rosand, J., Rosenberg, M. A., Rost, N., Rotter, J. I., Saba, S., Sandhu, R. K., Schnabel, R. B., Schramm, K., Schunkert, H., Schurman, C., Scott, S. A., Seppälä, I., Shaffer, C., Shah, S., Shalaby, A. A., Shim, J., Shoemaker, M. B., Siland, J. E., Sinisalo, J., Sinner, M. F., Slowik, A., Smith, A. V., Smith, B. H., Smith, J. G., Smith, J. D., Smith, N. L., Soliman, E. Z., Sotoodehnia, N., Stricker, B. H., Sun, A., Sun, H., Svendsen, J. H., Tanaka, T., Tanriverdi, K., Taylor, K. D., Teder-Laving, M., Teumer, A., Thériault, S., Trompet, S., Tucker, N. R., Tveit, A., Uitterlinden, A. G., Van Der Harst, P., Van Gelder, I. C., Van Wagener, D. R., Verweij, N., Vlachopoulou, E., Völker, U., Wang, B., Weeke, P. E., Weijs, B., Weiss, R., Weiss, S., Wells, Q. S., Wiggins, K. L., Wong, J. A., Woo, D., Worrall, B. B., Yang, P. S., Yao, J., Yoneda, Z. T., Zeller, T., Zeng, L., Lubitz, S. A., Lunetta, K. L. and Ellinor, P. T. (2018) Multi-ethnic genome-wide association study for atrial fibrillation. *Nature genetics*. **50**, 1225-1233
- 12 Wang, B., Lunetta, K. L., Dupuis, J., Lubitz, S. A., Trinquart, L., Yao, L., Ellinor, P. T., Benjamin, E. J. and Lin, H. (2020) Integrative Omics Approach to Identifying Genes Associated With Atrial Fibrillation. *Circulation research*. **126**, 350-360
- 13 Jia, W., Qi, X. and Li, Q. (2016) Association Between Rs3807989 Polymorphism in Caveolin-1 (CAV1) Gene and Atrial Fibrillation: A Meta-Analysis. *Medical science monitor : international medical journal of experimental and clinical research*. **22**, 3961-3966
- 14 Jiang, Y. F., Chen, M., Zhang, N. N., Yang, H. J., Xu, L. B., Rui, Q., Sun, S. J., Yao, J. L. and Zhou, Y. F. (2017) Association between KCNE1 G38S gene polymorphism and risk of atrial fibrillation: A PRISMA-compliant meta-analysis. *Medicine*. **96**, e7253
- 15 Zhang, Y. Q., Jiang, Y. F., Hong, L., Yang, H. J., Zhang, J. Y. and Zhou, Y. F. (2019) Role of Endothelial Nitric Oxide Synthase Polymorphisms in Atrial Fibrillation: A PRISMA-Compliant Meta-Analysis. *Medical science monitor : international medical journal of experimental and clinical research*. **25**, 2687-2694
- 16 Benjamin, E. J., Rice, K. M., Arking, D. E., Pfeufer, A., van Noord, C., Smith, A. V., Schnabel, R. B., Bis, J. C., Boerwinkle, E., Sinner, M. F., Dehghan, A., Lubitz, S. A., D'Agostino, R. B., Sr., Lumley, T., Ehret, G. B., Heeringa, J., Aspelund, T., Newton-Cheh, C., Larson, M. G., Marcante, K. D., Soliman, E. Z., Rivadeneira, F., Wang, T. J., Eiriksdottir, G., Levy, D., Psaty, B. M., Li, M., Chamberlain, A. M., Hofman, A., Vasan, R. S., Harris, T. B., Rotter, J. I., Kao, W. H., Agarwal, S. K., Stricker, B. H., Wang, K., Launer, L. J., Smith, N. L., Chakravarti, A., Uitterlinden, A. G., Wolf, P. A., Sotoodehnia, N., Köttgen, A., van Duijn, C. M., Meitinger, T., Mueller, M., Perz, S., Steinbeck, G., Wichmann, H. E., Lunetta, K. L., Heckbert, S. R., Gudnason, V., Alonso, A., Kääb, S., Ellinor, P. T. and Witteman, J. C. (2009) Variants in ZFX3 are associated with atrial fibrillation in individuals of European ancestry. *Nature genetics*. **41**, 879-881

- 17 Gudbjartsson, D. F., Holm, H., Gretarsdottir, S., Thorleifsson, G., Walters, G. B., Thorgeirsson, G., Gulcher, J., Mathiesen, E. B., Njølstad, I., Nyrnes, A., Wilsgaard, T., Hald, E. M., Hveem, K., Stoltenberg, C., Kucera, G., Stubblefield, T., Carter, S., Roden, D., Ng, M. C., Baum, L., So, W. Y., Wong, K. S., Chan, J. C., Gieger, C., Wichmann, H. E., Gschwendtner, A., Dichgans, M., Kuhlenbäumer, G., Berger, K., Ringelstein, E. B., Bevan, S., Markus, H. S., Kostulas, K., Hillert, J., Sveinbjörnsdóttir, S., Valdimarsson, E. M., Løchen, M. L., Ma, R. C., Darbar, D., Kong, A., Arnar, D. O., Thorsteinsdottir, U. and Stefansson, K. (2009) A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. *Nature genetics*. **41**, 876-878
- 18 Kalinderi, K., Fragakis, N., Sotiriadou, M., Oriol, D. I., Katritsis, D., Letsas, K., Korantzopoulos, P., Karamanolis, A., Pagourelas, E., Antoniadis, A. P., Dalampyras, P., Mavroudi, M., Kyriakou, P., Papadopoulos, C., Skeberis, V., Vassilikos, V. and Fidani, L. (2018) PRRX1 Rs3903239 polymorphism and atrial fibrillation in a Greek population. *Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese*. **59**, 298-299
- 19 Ihida-Stansbury, K., McKean, D. M., Gebb, S. A., Martin, J. F., Stevens, T., Nemenoff, R., Akeson, A., Vaughn, J. and Jones, P. L. (2004) Paired-related homeobox gene Prx1 is required for pulmonary vascular development. *Circulation research*. **94**, 1507-1514
- 20 Dolmatova, E., Cooper, R. R. and Ellinor, P. T. (2012) Prrx1 Interacts with and Inhibits Pitx2 Function. *Circulation*. **126**, A19452
- 21 Ellinor, P. T., Lunetta, K. L., Albert, C. M., Glazer, N. L., Ritchie, M. D., Smith, A. V., Arking, D. E., Müller-Nurasyid, M., Krijthe, B. P., Lubitz, S. A., Bis, J. C., Chung, M. K., Dörr, M., Ozaki, K., Roberts, J. D., Smith, J. G., Pfeufer, A., Sinner, M. F., Lohman, K., Ding, J., Smith, N. L., Smith, J. D., Rienstra, M., Rice, K. M., Van Wagener, D. R., Magnani, J. W., Wakili, R., Clauss, S., Rotter, J. I., Steinbeck, G., Launer, L. J., Davies, R. W., Borkovich, M., Harris, T. B., Lin, H., Völker, U., Völzke, H., Milan, D. J., Hofman, A., Boerwinkle, E., Chen, L. Y., Soliman, E. Z., Voight, B. F., Li, G., Chakravarti, A., Kubo, M., Tedrow, U. B., Rose, L. M., Ridker, P. M., Conen, D., Tsunoda, T., Furukawa, T., Sotoodehnia, N., Xu, S., Kamatani, N., Levy, D., Nakamura, Y., Parvez, B., Mahida, S., Furie, K. L., Rosand, J., Muhammad, R., Psaty, B. M., Meitinger, T., Perz, S., Wichmann, H. E., Witteman, J. C., Kao, W. H., Kathiresan, S., Roden, D. M., Uitterlinden, A. G., Rivadeneira, F., McKnight, B., Sjögren, M., Newman, A. B., Liu, Y., Gollob, M. H., Melander, O., Tanaka, T., Stricker, B. H., Felix, S. B., Alonso, A., Darbar, D., Barnard, J., Chasman, D. I., Heckbert, S. R., Benjamin, E. J., Gudnason, V. and Kääb, S. (2012) Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nature genetics*. **44**, 670-675
- 22 Huang, Y., Wang, C., Yao, Y., Zuo, X., Chen, S., Xu, C., Zhang, H., Lu, Q., Chang, L., Wang, F., Wang, P., Zhang, R., Hu, Z., Song, Q., Yang, X., Li, C., Li, S., Zhao, Y., Yang, Q., Yin, D., Wang, X., Si, W., Li, X., Xiong, X., Wang, D., Huang, Y., Luo, C., Li, J., Wang, J., Chen, J., Wang, L., Wang, L., Han, M., Ye, J., Chen, F., Liu, J., Liu, Y., Wu, G., Yang, B., Cheng, X., Liao, Y., Wu, Y., Ke, T., Chen, Q., Tu, X., Elston, R., Rao, S., Yang, Y., Xia, Y. and Wang, Q. K. (2015) Molecular Basis of Gene-Gene Interaction: Cyclic Cross-Regulation of Gene Expression and Post-GWAS Gene-Gene Interaction Involved in Atrial Fibrillation. *PLoS genetics*. **11**, e1005393
- 23 Liu, Y., Ni, B., Lin, Y., Chen, X. G., Chen, M., Hu, Z. and Zhang, F. (2015) The rs3807989 G/A polymorphism in CAV1 is associated with the risk of atrial fibrillation in Chinese Han populations. *Pacing and clinical electrophysiology : PACE*. **38**, 164-170
- 24 Liu, Y., Ni, B., Lin, Y., Chen, X. G., Fang, Z., Zhao, L., Hu, Z. and Zhang, F. (2014) Genetic polymorphisms in ZFHX3 are associated with atrial fibrillation in a Chinese Han population. *PloS one*. **9**, e101318
- 25 Okubo, Y., Nakano, Y., Ochi, H., Onohara, Y., Tokuyama, T., Motoda, C., Amioka, M., Hironobe, N., Okamura, S., Ikeuchi, Y., Miyauchi, S., Chayama, K. and Kihara, Y. (2020) Predicting atrial fibrillation using a combination of genetic risk score and clinical risk factors. *Heart rhythm*. **17**, 699-705
- 26 Tomomori, S., Nakano, Y., Ochi, H., Onohara, Y., Sairaku, A., Tokuyama, T., Motoda, C., Matsumura, H., Amioka, M., Hironobe, N., Ookubo, Y., Okamura, S., Kawazoe, H., Chayama, K. and Kihara, Y. (2018) Maintenance of low inflammation level by the ZFHX3 SNP rs2106261 minor allele contributes to reduced atrial fibrillation recurrence after pulmonary vein isolation. *PloS one*. **13**, e0203281
- 27 Zaw, K. T. T., Sato, N., Ikeda, S., Thu, K. S., Mieno, M. N., Arai, T., Mori, S., Furukawa, T., Sasano, T., Sawabe, M., Tanaka, M. and Muramatsu, M. (2017) Association of ZFHX3 gene variation with atrial fibrillation, cerebral infarction, and lung thromboembolism: An autopsy study. *Journal of cardiology*. **70**, 180-184
- 28 Wells, G., Shea, B., O'Connell, D., Robertson, J., Peterson, J., Welch, V., Losos, M. and Tugwell, P. (21 Oct, 2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In Ottawa Health Research Institute. ed.)^eds.)
- 29 DerSimonian, R. and Laird, N. (1986) Meta-analysis in clinical trials. *Controlled clinical trials*. **7**, 177-188

- 30 Mantel, N. and Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. *Journal of the National Cancer Institute.* **22**, 719-748
- 31 Hayashino, Y., Noguchi, Y. and Fukui, T. (2005) Systematic evaluation and comparison of statistical tests for publication bias. *Journal of epidemiology.* **15**, 235-243
- 32 Napolioni, V. (2014) The relevance of checking population allele frequencies and Hardy-Weinberg Equilibrium in genetic association studies: the case of SLC6A4 5-HTTLPR polymorphism in a Chinese Han Irritable Bowel Syndrome association study. *Immunology letters.* **162**, 276-278
- 33 Shao, H. B., Ren, K., Gao, S. L., Zou, J. G., Mi, Y. Y., Zhang, L. F., Zuo, L., Okada, A. and Yasui, T. (2018) Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancer. *Aging.* **10**, 1776-1788
- 34 Anderson, J. L., Halperin, J. L., Albert, N. M., Bozkurt, B., Brindis, R. G., Curtis, L. H., DeMets, D., Guyton, R. A., Hochman, J. S., Kovacs, R. J., Ohman, E. M., Pressler, S. J., Sellke, F. W., Shen, W. K., Wann, L. S., Curtis, A. B., Ellenbogen, K. A., Estes, N. A., 3rd, Ezekowitz, M. D., Jackman, W. M., January, C. T., Lowe, J. E., Page, R. L., Slotwiner, D. J., Stevenson, W. G., Tracy, C. M., Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Le Heuzey, J. Y., Kay, G. N., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L. and Wann, S. (2013) Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology.* **61**, 1935-1944
- 35 Piccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N., Hernandez, A. F., Heckbert, S. R., Benjamin, E. J. and Curtis, L. H. (2012) Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. *Circulation. Cardiovascular quality and outcomes.* **5**, 85-93
- 36 Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V. and Singer, D. E. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *Jama.* **285**, 2370-2375
- 37 Benjamin, E. J., Levy, D., Vaziri, S. M., D'Agostino, R. B., Belanger, A. J. and Wolf, P. A. (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *Jama.* **271**, 840-844
- 38 Gami, A. S., Pressman, G., Caples, S. M., Kanagala, R., Gard, J. J., Davison, D. E., Malouf, J. F., Ammash, N. M., Friedman, P. A. and Somers, V. K. (2004) Association of atrial fibrillation and obstructive sleep apnea. *Circulation.* **110**, 364-367
- 39 Creemers, E. E., Wilde, A. A. and Pinto, Y. M. (2011) Heart failure: advances through genomics. *Nature reviews. Genetics.* **12**, 357-362
- 40 Fu, X., Ma, X., Zhong, L. and Song, Z. (2015) Relationship between CYP11B2-344T>C polymorphsim and atrial fibrillation: A meta-analysis. *Journal of the renin-angiotensin-aldosterone system : JRAAS.* **16**, 185-188
- 41 He, J., Zhu, W., Yu, Y., Hu, J. and Hong, K. (2018) Variant rs2200733 and rs10033464 on chromosome 4q25 are associated with increased risk of atrial fibrillation after catheter ablation: Evidence from a meta-analysis. *Cardiology journal.* **25**, 628-638
- 42 Li, Y. Y., Wang, L. S. and Lu, X. Z. (2014) Mink S38G gene polymorphism and atrial fibrillation in the Chinese population: a meta-analysis of 1871 participants. *TheScientificWorldJournal.* **2014**, 768681
- 43 Rattanawong, P., Chenbhanich, J., Vutthikraivit, W. and Chongsathidkiet, P. (2018) A Chromosome 4q25 Variant is Associated with Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-Analysis. *Journal of atrial fibrillation.* **10**, 1666

Tables

Table 1 Characteristics of studies of ZFH3 and PRRX1 genes' two common polymorphisms and atrial fibrillation risk included in our meta-analysis

Author	Year	Country	Ethnicity	Case	Control	Case			Control			SOC	HWE	Genotype	NOS	AF type
ZFHX3 rs2106261						AA	AG	GG	AA	AG	GG					
Okubo	2020	Japan	Asian	289	287	46	143	99	32	109	146	HB	0.096	TaqMan	8	NA
Zaw	2017	Japan	Asian	411	1765	54	182	175	151	725	889	HB	0.853	Illumina	8	NA
Huang	2015	China	Asian	569	1996	99	237	233	216	869	911	PB	0.683	HRM	9	A
Huang	2015	China	Asian	641	1692	103	279	259	197	707	788	PB	0.048	HRM	9	A
Huang	2015	China	Asian	810	1627	128	369	313	149	726	752	PB	0.163	HRM	9	A
Liu	2014	China	Asian	593	996	110	299	184	99	446	451	HB	0.460	MassARRAY	8	paroxysmal AF
Tomomori	2018	Japan	Asian	362	627	50	181	131	60	250	317	HB	0.298	TaqMan	8	paroxysmal AF
PRRX1 rs3903239						CC	CT	TT	CC	CT	TT					
Kalinderi	2018	Greece	European	167	124	15	62	90	8	49	67	PB	0.809	RCR-RFLP	7	NA
Okubo	2020	Japan	Asian	287	287	29	139	119	59	143	85	HB	0.935	TaqMan	8	NA
Liu	2015	China	Asian	591	996	79	263	249	155	463	378	HB	0.503	MassARRAY	8	Mixed

HB: hospital-based; PB: population-based; SOC: source of control; PCR-RFLP: polymerase chain reaction followed by restriction fragment length polymorphism; HRM: High-Resolution Melt; HWE: Hardy-Weinberg equilibrium of control group; NA: not available.

Table 2 Stratified analyses of ZFHX3 and PRRX1 genes’ two common polymorphisms on atrial fibrillation risk
P_h: value of *Q*-test for heterogeneity test; *P*: Z-test for the statistical significance of the OR

Variables	N	Case/	M-allele vs. W-allele				MW vs. WW				MM+MW vs. WW				MM vs. WW				MM vs. MW+WW			
ZFHX3 rs2106261		Control	OR(95%CI)	<i>P_h</i>	<i>P</i>	<i>I²</i>	OR(95%CI)	<i>P_h</i>	<i>P</i>	<i>I²</i>	OR(95%CI)	<i>P_h</i>	<i>P</i>	<i>I²</i>	OR(95%CI)	<i>P_h</i>	<i>P</i>	<i>I²</i>	OR(95%CI)	<i>P_h</i>	<i>P</i>	<i>I²</i>
Total	7	3674/8990	1.39(1.31-1.47)0.117	0.000			1.37(1.18-1.59)0.007	0.000			1.49(1.30-1.70)0.011	0.000			1.96(1.73-2.21)0.317	0.000			1.70(1.52-1.90)0.643			
SOC			41.1%				66.5%				63.6%				14.8%				0.000	0.0%		
HB	4	1654/3675	1.51(1.38-1.64)0.302	0.000			1.57(1.38-1.79)0.156	0.000			1.68(1.49-1.90)0.151	0.000			2.20(1.82-2.66)0.388	0.000			1.73(1.45-2.07)0.520			
			17.7%				42.5%				43.4%				0.7%				0.000	0.0%		
PB	3	2020/5315	1.31(1.21-1.41)0.321	0.000			1.17(1.04-1.30)0.584	0.007			1.29(1.16-1.43)0.655	0.000			1.81(1.54-2.12)0.417	0.000			1.68(1.45-1.94)0.384			
			0.0%				0.0%				0.0%				0.0%				0.000	0.0%		
Genotype																						
TaqMan	2	650/914	1.55(1.33-1.80)0.740				1.82(1.46-2.27)0.668				1.87(1.52-2.30)0.674				2.06(1.48-2.86)0.884				1.51(1.11-2.06)1.000			
			0.000	0.0%			0.000	0.0%			0.000	0.0%			0.000	0.0%			0.000	0.0%		
Other	2	1004/2761	1.47(1.21-1.80)0.068	0.000			1.45(1.24-1.70)0.123	0.000			1.59(1.19-2.12)0.057	0.002			1.47(1.21-1.80)0.095	0.000			1.86(1.50-2.32)0.279			
			70.1%				58.1%				72.4%				64.1%				0.000	14.5%		
HRM	3	2020/5315	1.31(1.21-1.41)0.647	0.000			1.17(1.04-1.30)0.584	0.007			1.29(1.16-1.43)0.655	0.000			1.81(1.54-2.12)0.417	0.000			1.68(1.45-1.94)0.384			
			0.0%				0.0%				0.0%				0.0%				0.000	0.4%		
PRRX1 rs3903239																						
Total	3	1045/1407	0.82(0.63-1.07)0.023	0.147			0.83(0.77-0.99)0.522	0.036			0.79(0.67-0.94)0.137	0.006			0.68(0.35-1.32)0.011	0.253			0.75(0.42-1.31)0.023			
			73.5%				0.0%				49.7%				78.0%				0.310	73.5%		

Table 3 Publication bias tests (Begg’s funnel plot and Egger’s test for publication bias test)
for ZFHX3 and PRRX1 genes’ two common polymorphisms (rs2106261 and rs3903239)

Egger's test						Begg's test	
Genetic type	Coefficient	Standard error	t	P value	95%CI of intercept	z	P value
ZFHX3 rs2106261							
A-allele vs. G-allele	3.372	2.313	1.46	0.205	(-2.573- 9.317)	1.2	0.23
AG vs. GG	2.523	1.507	1.67	0.155	(-1.351- 6.398)	1.2	0.23
AA+AG vs. GG	2.744	1.543	1.78	0.133	(-1.223- 6.712)	1.2	0.23
AA vs. GG	1.671	0.977	1.71	0.148	(-0.840- 4.182)	1.2	0.23
AA vs. AG+GG	1.690	1.083	1.56	0.179	(-1.094- 4.475)	1.2	0.23
PRRX1 rs3903239							
C-allele vs. T-allele	1.034	9.771	0.11	0.933	(-123.117-125.186)	0.0	1.00
CT vs. TT	0.496	7.243	0.07	0.956	(-91.538-92.531)	0.0	1.00
CC+CT vs. TT	0.471	7.530	0.06	0.960	(-95.213-96.154)	0.0	1.00
CC vs. TT	0.251	3.834	0.07	0.958	(-48.468-48.971)	0.0	1.00
CC vs. CT+TT	0.290	4.031	0.07	0.954	(-50.938-51.519)	0.0	1.00

Figure 1

A flowchart showing the search strategy applied to search related papers for ZFHX3 rs2106261 and PRRX1 rs3903239 polymorphisms and AF risk.

A **B**

Figure 2

MAF for the gene polymorphisms among different ethnicity. Vertical line, MAF; Horizontal line, ethnicity type. EAS: East Asian; EUR: European; AFR: African; AMR: American; SAS: South Asian. A: rs2106261, B: rs3903239.

Figure 3

Forest plot of AF risk associated with ZFH3 rs2106261 polymorphism in all genetic models by source of control subgroup. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI. A: A-allele vs. C-allele; B: AC vs. CC; C: AA vs. CC; D: AA+AC vs. CC; E: AA vs. AC+CC.

Figure 4

Forest plot of AF risk associated with ZFH3 rs2106261 polymorphism in genotype method subgroup. A: A-allele vs. C-allele (fixed-model); B: A-allele vs. C-allele (random-model); C: AC vs. CC; D: AA+AC vs. CC (fixed-model); E: AA+AC vs. CC (random-model); F: AA vs. CC (fixed-model); G: AA vs. CC (random-model); H: AA vs. AC+CC.

A

B

Figure 5

Forest plot of AF risk associated with PRRX1 rs3903239 polymorphism in the whole analysis. A: heterozygote comparison; B: dominant model.

Figure 6

Begg's and Egger's tests for publication bias plot in all genetic models (ZFHX3 rs2106261 polymorphism). A: A-allele vs. C-allele; B: AC vs. CC; C: AA vs. CC; D: AA+AC vs. CC; E: AA vs. AC+CC for Begg's test. F: A-allele vs. C-allele; G: AC vs. CC; H: AA vs. CC; I: AA+AC vs. CC; J: AA vs. AC+CC for Egger's test.

Figure 7

Begg's and Egger's tests for publication bias plot in all two models (PRRX1 rs3903239 polymorphism). A: heterozygote comparison; B: dominant model.

Figure 8

Sensitivity analysis between ZFH3 rs2106261 polymorphism and AF risk (all five genetic models). A: A-allele vs. C-allele; B: AC vs. CC; C: AA vs. CC; D: AA+AC vs. CC; E: AA vs. AC+CC.

Figure 9

Human ZFH3 and PRRX1 genes interactions network with other genes obtained from String online server. At least 10 genes have been indicated to correlate with above two genes, respectively. A,C: network and ten related genes for ZFH3 gene; B,D: network and ten related genes for PRRX1 gene.